Intellia sees path to take CRISPR into eye via SparingVision

Intellia is building on this summer’s early clinical proof-of-concept data for its gene editing platform with an ophthalmology deal with SparingVision, the CRISPR company’s first move into the space. 

Intellia Therapeutics Inc. (NASDAQ:NTLA) is licensing rights to its coveted foundational CRISPR-Cas9 IP to SparingVision S.A.S for therapies against three ophthalmology targets in exchange for 10% equity in the preclinical biotech and about $200 million in milestones per program, plus royalties. ...